Bioniz Therapeutics is a private biopharmaceutical company leading the discovery and development of first-in-class anti-cytokine therapies to treat cancer and autoimmune diseases driven by unregulated T-cell biology. Bioniz leverages its world class expertise in cytokine biology to develop a pipeline of novel peptide therapeutics to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact.
The company’s lead product candidate, BNZ-1, has successfully completed a Phase 1/2 clinical trial in Refractory Cutaneous T-cell lymphoma (rCTCL). Bioniz is also evaluating BNZ-1 for the treatment of autoimmune diseases, including alopecia areata and vitiligo. BNZ-2 and BNZ-3 are being developed as potential treatments for celiac disease and inflammatory bowel disease.
Location: United States, California, Irvine
Member count: 11-50
Total raised: $13M
Founded date: 2010
Investors 3
Date | Name | Website |
15.09.2021 | Broadway A... | broadway-a... |
- | Takeda Ven... | takeda.com |
- | Cota Capit... | cotacapita... |
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
01.08.2016 | - | $13M | - | socaltech.... |
Mentions in press and media 3
Date | Title | Description | Category | Author | Source |
19.08.2016 | OCTANe’s a... | “When a company comes through ... | - | - | medcitynew... |
01.08.2016 | Bioniz... | Irvine-based Bioniz Therapeuti... | - | - | socaltech.... |
- | OCTANe’s a... | Startups have a burning need t... | - | - | medcitynew... |